Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8RI5

Crystal structure of transplatin/B-DNA adduct obtained upon 48 h of soaking

Summary for 8RI5
Entry DOI10.2210/pdb8ri5/pdb
DescriptorDNA (5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'), MAGNESIUM ION, AMMONIA, ... (5 entities in total)
Functional Keywordsb-dna, dodecamer, dickerson, platinum, interaction, dna
Biological sourceDNA molecule
Total number of polymer chains2
Total formula weight7563.20
Authors
Tito, G.,Troisi, R.,Ferraro, G.,Sica, F.,Merlino, A. (deposition date: 2023-12-18, release date: 2024-02-07, Last modification date: 2024-02-28)
Primary citationTroisi, R.,Tito, G.,Ferraro, G.,Sica, F.,Massai, L.,Geri, A.,Cirri, D.,Messori, L.,Merlino, A.
On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Dalton Trans, 53:3476-3483, 2024
Cited by
PubMed Abstract: The reaction of Pt-based anticancer agents with arsenic trioxide affords robust complexes known as arsenoplatins. The prototype of this family of anticancer compounds is arsenoplatin-1 (AP-1) that contains an As(OH) fragment linked to a Pt(II) moiety derived from cisplatin. Crystallographic and spectrometric studies of AP-1 binding to a B-DNA double helix dodecamer are presented here, in comparison with cisplatin and transplatin. Results reveal that AP-1, cisplatin and transplatin react differently with the DNA model system. Notably, in the AP-1/DNA systems, the Pt-As bond can break down with time and As-containing fragments can be released. These results have implications for the understanding of the mechanism of action of arsenoplatins.
PubMed: 38270175
DOI: 10.1039/d3dt04302a
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.415 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon